Amyris Signs $300M Deal For Fermentation-Derived CBD Products
Amyris Inc (NASDAQ:AMRS) shares were rallying Tuesday following the announcement of a cannabinoid development, licensing and commercialization agreement.
Amyris, which produces ingredients in the health and wellness, clean beauty and flavors and fragrances markets, said it has clinched a deal with newly formed LAVVAN Inc., which is working on bringing the first fermentation-derived cannabinoid products to market.
The announcement comes after a previously announced term sheet and includes further milestone payments related to additional targeted products.
Amyris, with its expertise in terpenes, said it will leverage its automated processes and R&D staff in the development of cannabinoid pathways.
The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Danny Moses, Alan Brochstein and many others.
LAVVAN will take up the global manufacture and commercialization of cannabinoids. The agreement calls for LAVVAN to pay Amyris $300 million of R&D and milestone payments plus long-term royalties.
Amyris said it is confident of earning a significant portion of these milestone payments by the end of 2020, with $20 million to $30 million anticipated in 2019, including a $10-million milestone payment that is expected later this month.
Separately, Amyris reported fourth-quarter results Monday, with the company reversing to a loss of 76 cents per share on a non-GAAP basis from a profit of 76 cents in the year-ago period.
Why It's Important
CBD derived from fermentation is likely to have consistent purity and dosage and an improved yield of economically difficult-to-source "rare" CBS, according to Amyris.
"Based on our known success in bringing fermentation-based products to market and our demonstrated expertise in producing plant compounds in yeast, we have high confidence in achieving the partnership goals," Joel Cherry, president of R&D at Amyris, said in a statement.
Amyris shares were trading up 5.25 percent at $4.01 at the time of publication Tuesday.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.